Recursion Pharmaceuticals (RXRX) shares were up 14% in recent Wednesday trading after JPMorgan upgraded the stock to overweight from neutral, and adjusted its price target to $11 from $10.
Trading volume stood at over 55.2 million shares compared with a daily average of about 43.0 million shares.
Price: 4.78, Change: +0.58, Percent Change: +13.69